Legal Status Overview
Gray AreaPeptides have no Massachusetts-specific legal category: there is no state statute, administrative code (247 CMR), or Board of Registration in Pharmacy rule that names 'peptides' or 'research chemicals' as a distinct class, so the state defers to federal drug and compounding law. The Massachusetts Board of Registration in Pharmacy actively enforces the federal 503A/503B compounding scheme, having recently challenged a licensed compounder over sublingual semaglutide and restricted how 503B outsourcing facilities can supply 503A pharmacies. Because compounds like BPC-157 are treated by FDA as ineligible for compounding, and 'research-use-only' peptides sold outside a prescription/compounding chain are not FDA-approved drugs, their sale for human use is not lawful in Massachusetts, though this flows from federal law rather than a peptide-specific state ban.
Key Points
- Massachusetts has no statute, administrative code section, or Board of Registration in Pharmacy rule that names 'peptides,' 'research chemicals,' or research-use-only compounds as their own distinct legal category. [1]
- Massachusetts compounding pharmacies are regulated under 247 CMR 20.06 and related Board of Registration in Pharmacy rules, which incorporate the federal 503A (patient-specific compounding) and 503B (outsourcing facility) framework rather than a separate state peptide rule. [1]
- The Massachusetts Board of Registration in Pharmacy has actively challenged a state-licensed compounder over sublingual 'semaglutide' preparations, citing FDA's 'essentially a copy' guidance as grounds that the compounding was unlawful. [2]
- The Massachusetts Board has ruled that Massachusetts-based 503A retail pharmacies may not source compounded drugs from 503B outsourcing facilities, while out-of-state 503A pharmacies may still ship patient-specific compounded drugs into Massachusetts if sourced from an FDA-registered 503B. [2]
- Massachusetts' current strict approach to compounding oversight traces back to the 2012 New England Compounding Center fungal meningitis outbreak, a Massachusetts-based pharmacy incident that killed over 60 people nationwide and prompted Congress to pass the federal Drug Quality and Security Act in 2013. [4]
- A person cannot lawfully buy or import BPC-157 or similar unapproved research peptides for personal human use in Massachusetts because FDA has placed BPC-157 in a 'Category 2' do-not-compound status, and no Massachusetts-specific personal-importation allowance exists for it; this point reflects federal categorization applied within the state rather than a distinct Massachusetts import rule. [5]
- The only lawful pathway to obtain a peptide-class drug in Massachusetts is through an FDA-approved product dispensed under a valid prescription from a licensed prescriber, filled by a Massachusetts-registered pharmacy or an appropriately licensed 503A/503B compounder acting within federal limits. [7]
- Massachusetts, like most states, has not enacted its own substantive peptide-compounding statute beyond the federal 503A/503B baseline, relying instead on Board of Pharmacy enforcement actions and guidance rather than new legislation. [7]
Peptide-by-peptide status in Massachusetts
| BPC-157 | BPC-157 is not a legally compoundable or FDA-approved drug in Massachusetts because FDA has placed it in 'Category 2' (substances that present significant safety risks and should not be compounded), so its sale or compounding for human use is unlawful under the federal 503A/503B rules Massachusetts pharmacies must follow. [5] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | FDA-approved semaglutide and tirzepatide products (e.g., Ozempic, Wegovy, Rybelsus, Zepbound) are legal in Massachusetts only as prescription medicines, and the Massachusetts Board of Registration in Pharmacy has specifically challenged compounded/sublingual semaglutide preparations made by a licensed compounder as noncompliant with FDA's copy-drug guidance. [2] |
| TB-500 (thymosin beta-4 fragment) | No Massachusetts-specific statute or Board of Pharmacy rule addresses TB-500 by name, so its legal status in Massachusetts follows the general federal rule that unapproved, non-compoundable peptides sold for human use outside a valid prescription/compounding pathway are not lawfully marketed. |
| HGH / Somatropin | Human growth hormone (somatropin) is a federally controlled prescription drug under the Anabolic Steroids Control Act framework nationwide, so in Massachusetts it is legal only when dispensed under a valid prescription through a licensed pharmacy, with no Massachusetts-specific HGH statute identified in this research. |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides in Massachusetts without a prescription?
No, lawfully marketed peptide drugs (such as FDA-approved semaglutide products) require a valid prescription in Massachusetts, and unapproved research peptides like BPC-157 are not legal to sell for human use regardless of prescription because FDA has barred their compounding. [5]
Is it legal to bring peptides into Massachusetts for personal use?
No Massachusetts-specific personal-importation rule for peptides was found in this research, so travelers would be subject to general federal rules restricting importation of unapproved drugs, meaning bringing in unapproved research peptides carries legal risk even though Massachusetts has not enacted its own import statute.
Can a telehealth doctor legally prescribe peptides to someone in Massachusetts?
A telehealth prescriber can lawfully prescribe an FDA-approved peptide drug to a Massachusetts patient only if the prescription is filled by a properly licensed pharmacy operating within the federal 503A framework, but Massachusetts's Board of Registration in Pharmacy has shown it will scrutinize compounded versions (like sublingual semaglutide) that it deems noncompliant with FDA guidance. [2]
What penalties exist in Massachusetts for illegally compounding or selling peptides like BPC-157?
This research did not identify a Massachusetts-specific criminal penalty schedule for peptide sales; enforcement instead has occurred through Board of Registration in Pharmacy licensing actions (such as probation or registration consequences for compounding violations) rather than a dedicated peptide criminal statute.
Does Massachusetts have its own law banning research chemicals or peptides?
No, Massachusetts has no standalone law or Board of Pharmacy rule that specifically bans or categorizes 'research chemicals' or peptides as a class; the state instead applies its general compounding regulations (247 CMR) and defers to FDA's federal drug approval and compounding rules. [1]